All In Biotech

Drug Trial Radar · NCT07696351

Ultra-Long GnRH-a Pretreatment for FET Outcomes in Patients With Deep Infiltrating Endometriosis

A Randomized Controlled Study of Ultra-Long GnRH-a Pretreatment to Improve Frozen-Thawed Embryo Transfer Outcomes in Patients With Deep Infiltrating Endometriosis

Last checked: Nov 20, 2026Latest source record: Jul 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 120 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

120

Planned (sponsor's estimate)

Start

Aug 1, 2025

Primary completion

Dec 31, 2026

Study completion Jul 31, 2027

Sponsor

Lead sponsor
Li-jun DingAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jul 10, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Female only, from 18 years, up to 39 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Deep infiltrating endometriosis is a severe form of endometriosis that may reduce fertility and negatively affect pregnancy outcomes after assisted reproductive treatment. Gonadotropin-releasing hormone agonist pretreatment may suppress endometriotic lesions, reduce inflammation, and improve endometrial receptivity, but its benefit before frozen-thawed embryo transfer remains uncertain. This randomized controlled study will evaluate whether ultra-long GnRH-a pretreatment before hormone replacement therapy improves clinical pregnancy outcomes in patients with deep infiltrating endometriosis undergoing their first frozen-thawed embryo transfer cycle. Eligible participants will be randomly assigned to either the GnRH-a pretreatment group or the control group. Participants in the GnRH-a group will receive two injections of long-acting GnRH-a before hormone replacement therapy for endometrial preparation, while participants in the control group will receive routine hormone replacement therapy alone. The primary outcome is clinical pregnancy rate, defined as the presence of a gestational sac on transvaginal ultrasound 30 ± 3 days after embryo transfer. Secondary outcomes include implantation rate, ectopic pregnancy rate, early spontaneous abortion rate, ongoing pregnancy rate at 12 weeks of gestation, and delivery rate. Safety will be evaluated by recording adverse events after GnRH-a injection. The planned enrollment is 120 participants.

Conditions

  • Deep Infiltrating Endometriosis (DIE)
  • Infertility

Interventions

  • Triptorelin (GnRH agonists)Drug

    Long-acting GnRH-a pretreatment will be administered before hormone replacement therapy for endometrial preparation. Participants will receive two injections of triptorelin 3.75 mg: the first on menstrual cycle days 2 to 4 and the second 28 to 30 days later.

  • Hormone Replacement Therapy (HRT)Other

    Routine hormone replacement therapy will be used for endometrial preparation before frozen-thawed embryo transfer.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Clinical Pregnancy RateTime frame: 30 ± 3 days after embryo transfer

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The Affiliated Drum Tower Hospital of Nanjing University Medical School

    Nanjing, Jiangsu, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.